Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex Dosage for Rocuronium Reversal in Infants < 24 Months
NCT07477132Phase 4Not yet recruiting
- Sponsor
- CHU Caen Normandie
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Sugammadex in Postoperative residual curarization (PORC), sponsored by CHU Caen Normandie. Primary endpoint: Total dosage of sugammadex necessary to obtain a complete reversal of neuromuscular blockade up to 12 hours. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
Sugammadex
03
Conditions
Postoperative residual curarization (PORC)
Beyond the preview
Go deeper on NCT07477132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477132.